Data from the Phase III ZODIAC1 study in advanced non-small cell lung cancer patients, with the investigational drug vandetanib, were presented today at the American Society of Clinical Oncology (ASCO) meeting in Orlando. Continue reading ...
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment